FDMT 4D Molecular Therapeutics: חובות ארוכי טווח של החברה

4D Molecular Therapeutics develops advanced treatments for the heart and eyes, leveraging unique patents for immune evasion. The company is actively advancing clinical trials for innovative drugs. This chart on GURU.Markets shows that long-term debt stands at 0.04. Business stability is further supported by strict temperature control during the transport of biomaterials, ensuring therapy safety for patients.

4D Molecular Therapeutics maintains a strong position in the gene therapy sector thanks to its innovative vector platform. This metric measures the aggregate of credit obligations with a maturity of over one year, determining financial stability and the cost of borrowed capital. Analyzing the organization's long-term debt level allows for an assessment of the resources available to conduct costly clinical trials in the US. The stable trend of this indicator confirms the company's ability to scale development without a critical risk of default.